Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
EyePoint, Inc. completed a disposition involving Alimera Sciences, Inc. for Upfront payment of $75 million, four quarterly guaranteed payments totaling $7.5 million during 2024, and royalties from 2025 to 2028 at a percentage of low-to- (closed 2023-05-17).
- Action
- disposition
- Counterparty
- Alimera Sciences, Inc.
- Consideration
- Upfront payment of $75 million, four quarterly guaranteed payments totaling $7.5 million during 2024, and royalties from 2025 to 2028 at a percentage of low-to-
- Closing
- 2023-05-17
Exact text from the filing
(the “ Company ”) entered into a product rights agreement (the “ Product Rights Agreement ”) with Alimera Sciences, Inc. (“ Alimera ”) to grant to Alimera an exclusive (even as to the Company) and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the “ License ”) under the Company’s and its affiliates’ interest in certain of the Company’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world except Europe, the Middle East and Africa (the “ Licensed Territory ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
EyePoint, Inc. entered into Product Rights Agreement with Alimera Sciences, Inc. valued at $75 million (effective 2023-05-17).
- Action
- entry
- Agreement
- license
- Counterparty
- Alimera Sciences, Inc.
- Value
- $75 million
- Effective
- 2023-05-17
Exact text from the filing
On May 17, 2023 (the " Closing Date "), EyePoint Pharmaceuticals, Inc. (the " Company ") entered into a product rights agreement (the " Product Rights Agreement ") with Alimera Sciences, Inc. (" Alimera ") to grant to Alimera an exclusive (even as to the Company) and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the " License ") under the Company’s and its affiliates’ interest in certain of the Company’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world except Europe, the Middle East and Africa (the " Licensed Territory ").
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
EyePoint, Inc. announced a restructuring with charges of approximately $1.2 million to $1.6 million in total pre-tax charges affecting sales and marketing organization and other supporting roles (approximately 35 employees).
- Type
- restructuring
- Charge
- approximately $1.2 million to $1.6 million in total pre-tax charges
- Affected area
- sales and marketing organization and other supporting roles
- Headcount
- approximately 35 employees
Exact text from the filing
of a separation agreement, which includes a general release of claims against the Company. The Company estimates that the implementation of the RIF will result in approximately $1.2 million to $1.6 million in total pre-tax charges and cash outlays for termination of employees. The Company expects the charges will be incurred primarily in the second quarter of 2023,
View on SEC.gov